# RAG Benchmark — 2026-09-09

## Gemini Prompt 8192

**Q1:** Interviewer: Thanks for making time for this. Just to confirm, this conversation is being recorded for an internal reliability-process review, not a safety investigation into you personally — we're trying to understand how these calls actually get made in practice. That okay with you? Participant: Yeah, that's fine. Happy to walk through it. Interviewer: Great. Can you start by telling me your role and how this particular case landed on your desk? Participant: Sure. I'm a reliability engineer in Maintenance Control. Part of my job is watching for repetitive write-ups across the fleet and deciding when something crosses from 'normal noise' into something that needs a formal corrective action. This one came up because tail 738 logged a third APU bleed air valve write-up inside 45 flight days. Two earlier ones had been closed out as operational check normal, no parts changed, which is pretty typical — a lot of these clear on the bench. Interviewer: Walk me through the incident from the beginning, in your own words. Participant: So the third write-up on 738 is what actually got my attention, because three in that short a window is unusual even though our fleet-wide removal rate for that valve was still sitting inside the OEM's published MTBUR. Nothing screamed 'fleet problem' yet — it looked like it could just be a stubborn individual aircraft. I opened a focused review on that tail rather than calling it a fleet issue outright, and I put a flag on it so I'd get pinged if anything similar showed up elsewhere. Two days later it did — tail 712 logged a lower-severity version of basically the same complaint. That's when line maintenance told me the valve is genuinely hard to bench-test, which raised the possibility we had an intermittent fault that ground checks weren't catching. At that point I pulled the two tails' component histories together and found they shared the same valve batch lot number. That felt like a real thread to pull. Interviewer: What did you do with that lot-number connection? Participant: Company policy is we don't like repeated MEL carryover on the same defect — dispatching with the APU inoperative under MEL is allowed, but doing it leg after leg on the same fault is a flag in itself. Neither aircraft had had an actual in-flight consequence; both faults were caught on the ground. So grounding both outright felt like more than the evidence supported at that point. I put an interim restriction on — one leg of MEL carryover maximum, then it has to be addressed — on both tails, and opened a formal root-cause investigation tied to that lot number. Interviewer: What came back from that investigation? Participant: The vendor quality engineer confirmed that lot had a documented seal-material change about six months earlier. That's a real, traceable cause — not a guess. And our in-house teardown of the valve we'd pulled off 738 showed seal degradation that was consistent with exactly that material change. So by that point I had two independent lines — vendor documentation and physical teardown — pointing at the same thing. Interviewer: Let's slow down on that moment, because I want to understand what happened next. What were you weighing? Participant: Right, so this is the part before I finalized anything for the Reliability Control Board. I had ten days to the RCB deadline. The vendor's lot documentation and our own teardown already lined up on the seal material as the cause, and honestly I'd already decided in my own head that the corrective action was going to be a lot-bounded replacement — that part felt settled. But there was still an option to send the valve out to an external metallurgical lab for an independent composition assay, on top of what I already had. Interviewer: And what did you decide? Participant: I sent it out anyway. I'd basically landed on the lot-based replacement regardless of what came back — I wasn't holding the recommendation open pending that result. I think I just wanted a third, fully independent source in the file alongside the vendor's own account of their material, so the package read as more thorough when it went to the board. I knew the lab's turnaround was about three weeks, which meant we'd blow through the RCB deadline before that data came back, and I sent it anyway. Interviewer: At the time you sent it out, was there anything the assay could tell you that would have changed which corrective action you recommended? Participant: Not really, no. The recommendation was already written in my head — vendor records and physical teardown agreed, and that's what the corrective action request was going to be built on either way. I think I was after the reassurance of having one more test in the folder more than anything that would've moved the decision itself. Interviewer: What happened with the deadline? Participant: We missed presenting a finalized recommendation at that RCB cycle. It slipped to submit-pending-lab-results, even though the recommendation itself wasn't really pending on anything. When the assay results did eventually land, they confirmed the same seal-material change the vendor had already told us about — nothing new in it. Interviewer: Let's move to the final decision — what you actually recommended once everything was in. Participant: Once the root cause was locked down, the OEM tech rep raised the idea of a broader design review of the valve seal spec generally, as a longer-term option. But that's a slow, separate track. What I had in front of me was a specific, bounded problem: one vendor lot, identifiable serial ranges. I wrote the corrective action request to replace valves from that lot specifically, not a fleet-wide swap of every valve regardless of lot, and not just deferring to wait on the OEM's broader review. Interviewer: Why bounded to the lot rather than fleet-wide? Participant: Because a fleet-wide replacement would have pulled serviceable, unaffected valves for no reason — that's cost and downtime with no reliability benefit. The evidence pointed specifically at that lot, so that's what I scoped the action to. Interviewer: What happened after you submitted it? Participant: RCB approved the lot-based campaign. Both tails got their valves replaced, and there haven't been further events on either aircraft since. The OEM's broader design review got pushed into a separate long-term study, which is still open as far as I know. Interviewer: Looking back at the whole sequence — is there a point where, with hindsight, you'd handle it differently? Participant: The one thing I go back and forth on is the external lab. I already knew the recommendation wasn't going to move based on what it found — I'd have submitted the same lot-based request either way. Knowing that now, I probably should have just submitted on the original ten-day timeline using the vendor and teardown evidence and let the RCB approve on that, rather than holding the whole submission for a test that was only ever going to restate what I already had. Interviewer: If the assay had come back showing something different from the vendor's account — a different degradation mechanism, say — what would you have done? Participant: I'd have flagged it and opened a separate follow-up investigation into whether the lot-based campaign needed a second look. But that would've come after the fact — I wasn't planning to hold up this submission on that possibility, since I'd already committed to the lot-based recommendation before the assay went out. Interviewer: And if this exact pattern showed up again on a different fleet type — same lot-based signature, same timeline pressure — would you send it out for independent lab work again? Participant: Probably not on the same timeline, honestly. I think I'd ask myself earlier on whether the extra data was likely to change the recommendation I'd already reached or just make the file look better, and weigh that against the deadline more explicitly than I did this time. Interviewer: That's a good place to stop. Thanks for the detail — this is exactly the kind of reconstruction we needed. Participant: No problem. Happy to follow up if anything else comes to mind.

_ranker=rrf · t=0.04 · k=0 → 0 in context · 8192 ctx · emb 0.00s · gen 131.12s · total 135.5s_

_No chunks passed the similarity threshold._

{
  "analysis_metadata": {
    "task": "cognitive_bias_analysis",
    "interview_speakers_detected": ["Interviewer", "Participant"],
    "retrieved_corpus_support_used": false,
    "analysis_scope_note": "No retrieved corpus passages were supplied in the RAG context; the analysis used the interview transcript as the sole factual evidence and established cognitive-science knowledge for bias labeling."
  },
  "identified_bias_summary": [
    {
      "bias_label": "information bias",
      "identified_occurrence_count": 1
    }
  ],
  "identified_occurrences": [
    {
      "occurrence_id": "obs_001",
      "classification_status": "identified",
      "confidence": "moderate",
      "bias_label": "information bias",
      "alternative_labels": ["information seeking bias", "commission bias"],
      "taxonomy_status": "established_label",
      "bias_definition": "The tendency to seek additional information beyond what is needed for an imminent decision, often because more information is perceived as beneficial even when it cannot alter action, leading to delay or unnecessary testing.",
      "attributed_to_speaker": "Participant",
      "evidence_speaker": "Participant",
      "decision_episode_label": "Decision to send the APU bleed air valve for external metallurgical assay before the Reliability Control Board deadline",
      "decision_point_description": "Participant decided whether to order an additional independent lab assay despite already having sufficient vendor documentation and in-house teardown evidence and knowing the recommendation would not change.",
      "affected_reasoning_operation": "Evidence acquisition and deadline-sensitive action selection",
      "bias_specific_mechanism": "The participant acquired an additional lab test for reassurance or file completeness despite judging that the result would not alter the corrective-action recommendation and would cause the RCB deadline to slip.",
      "manifestation_in_interview": "The participant settled on a lot-bounded replacement recommendation, then sent the valve for external assay anyway, explicitly saying the lab result would not move the decision and that the three-week turnaround would miss the ten-day deadline.",
      "effect_on_reasoning_or_decision": "The choice delayed presentation of a finalized recommendation beyond the RCB cycle, producing an avoidable schedule slip without changing the corrective action.",
      "interview_evidence": [
        {
          "speaker": "Participant",
          "verbatim_quote": "I sent it out anyway. I'd basically landed on the lot-based replacement regardless of what came back — I wasn't holding the recommendation open pending that result. I think I just wanted a third, fully independent source in the file alongside the vendor's own account of their material, so the package read as more thorough when it went to the board. I knew the lab's turnaround was about three weeks, which meant we'd blow through the RCB deadline before that data came back, and I sent it anyway.",
          "evidence_explanation": "This explicitly shows the participant ordered the test while knowing the result would not change the recommendation and would miss the deadline, with the motive being file thoroughness rather than decision relevance."
        },
        {
          "speaker": "Participant",
          "verbatim_quote": "Not really, no. The recommendation was already written in my head — vendor records and physical teardown agreed, and that's what the corrective action request was going to be built on either way. I think I was after the reassurance of having one more test in the folder more than anything that would've moved the decision itself.",
          "evidence_explanation": "This demonstrates that the information was sought for reassurance rather than because it could influence the pending recommendation, which is the core mechanism of information bias."
        },
        {
          "speaker": "Participant",
          "verbatim_quote": "We missed presenting a finalized recommendation at that RCB cycle. It slipped to submit-pending-lab-results, even though the recommendation itself wasn't really pending on anything.",
          "evidence_explanation": "This confirms the operational consequence: the deadline slipped even though the recommendation was not logically contingent on the additional test."
        }
      ],
      "correction_or_counterevidence": "A legitimate professional due-diligence norm could favor a thorough independent evidentiary record for the Reliability Control Board. However, the participant explicitly stated the recommendation was already settled and not pending the assay, and later judged the deadline slip avoidable, which supports information bias rather than a purely rational or mandated due-diligence action.",
      "retrieved_corpus_support_available": false,
      "corpus_support_note": "No retrieved scientific passages were supplied in the RAG context; this classification relies on established cognitive-science knowledge of information bias and related commission bias.",
      "corpus_evidence": []
    }
  ],
  "candidate_biases": [
    {
      "candidate_id": "cand_001",
      "classification_status": "candidate",
      "proposed_bias_label": "confirmation bias",
      "alternative_labels": ["confirmatory information seeking"],
      "taxonomy_status": "established_label",
      "speaker_or_attributed_person": "Participant",
      "possible_decision_episode_label": "Decision to send valve for external assay after forming a preliminary recommendation",
      "supporting_interview_quote": "I think I was after the reassurance of having one more test in the folder more than anything that would've moved the decision itself.",
      "plausible_mechanism": "Seeking additional information primarily to corroborate a preferred conclusion rather than to discriminate between alternative recommendations.",
      "why_not_identified": "The transcript does not show biased evaluation, discounting, or rejection of a disconfirming result; the participant said a discrepant assay would have triggered a separate follow-up investigation, so the primary distortion is seeking non-actionable information rather than confirmatory evaluation."
    }
  ],
  "no_supported_biases_found": false,
  "limitations": [
    "No retrieved corpus passages were provided; bias labeling and mechanisms are grounded in the transcript and established cognitive-science knowledge rather than retrieved literature.",
    "The analysis is based on a single self-reported interview; operational constraints or organizational norms that might further explain the decision cannot be independently verified."
  ]
}

## Sonar Prompt 8192

**Q1:** Interviewer: Thanks for making time for this. Just to confirm, this conversation is being recorded for an internal reliability-process review, not a safety investigation into you personally — we're trying to understand how these calls actually get made in practice. That okay with you? Participant: Yeah, that's fine. Happy to walk through it. Interviewer: Great. Can you start by telling me your role and how this particular case landed on your desk? Participant: Sure. I'm a reliability engineer in Maintenance Control. Part of my job is watching for repetitive write-ups across the fleet and deciding when something crosses from 'normal noise' into something that needs a formal corrective action. This one came up because tail 738 logged a third APU bleed air valve write-up inside 45 flight days. Two earlier ones had been closed out as operational check normal, no parts changed, which is pretty typical — a lot of these clear on the bench. Interviewer: Walk me through the incident from the beginning, in your own words. Participant: So the third write-up on 738 is what actually got my attention, because three in that short a window is unusual even though our fleet-wide removal rate for that valve was still sitting inside the OEM's published MTBUR. Nothing screamed 'fleet problem' yet — it looked like it could just be a stubborn individual aircraft. I opened a focused review on that tail rather than calling it a fleet issue outright, and I put a flag on it so I'd get pinged if anything similar showed up elsewhere. Two days later it did — tail 712 logged a lower-severity version of basically the same complaint. That's when line maintenance told me the valve is genuinely hard to bench-test, which raised the possibility we had an intermittent fault that ground checks weren't catching. At that point I pulled the two tails' component histories together and found they shared the same valve batch lot number. That felt like a real thread to pull. Interviewer: What did you do with that lot-number connection? Participant: Company policy is we don't like repeated MEL carryover on the same defect — dispatching with the APU inoperative under MEL is allowed, but doing it leg after leg on the same fault is a flag in itself. Neither aircraft had had an actual in-flight consequence; both faults were caught on the ground. So grounding both outright felt like more than the evidence supported at that point. I put an interim restriction on — one leg of MEL carryover maximum, then it has to be addressed — on both tails, and opened a formal root-cause investigation tied to that lot number. Interviewer: What came back from that investigation? Participant: The vendor quality engineer confirmed that lot had a documented seal-material change about six months earlier. That's a real, traceable cause — not a guess. And our in-house teardown of the valve we'd pulled off 738 showed seal degradation that was consistent with exactly that material change. So by that point I had two independent lines — vendor documentation and physical teardown — pointing at the same thing. Interviewer: Let's slow down on that moment, because I want to understand what happened next. What were you weighing? Participant: Right, so this is the part before I finalized anything for the Reliability Control Board. I had ten days to the RCB deadline. The vendor's lot documentation and our own teardown already lined up on the seal material as the cause, and honestly I'd already decided in my own head that the corrective action was going to be a lot-bounded replacement — that part felt settled. But there was still an option to send the valve out to an external metallurgical lab for an independent composition assay, on top of what I already had. Interviewer: And what did you decide? Participant: I sent it out anyway. I'd basically landed on the lot-based replacement regardless of what came back — I wasn't holding the recommendation open pending that result. I think I just wanted a third, fully independent source in the file alongside the vendor's own account of their material, so the package read as more thorough when it went to the board. I knew the lab's turnaround was about three weeks, which meant we'd blow through the RCB deadline before that data came back, and I sent it anyway. Interviewer: At the time you sent it out, was there anything the assay could tell you that would have changed which corrective action you recommended? Participant: Not really, no. The recommendation was already written in my head — vendor records and physical teardown agreed, and that's what the corrective action request was going to be built on either way. I think I was after the reassurance of having one more test in the folder more than anything that would've moved the decision itself. Interviewer: What happened with the deadline? Participant: We missed presenting a finalized recommendation at that RCB cycle. It slipped to submit-pending-lab-results, even though the recommendation itself wasn't really pending on anything. When the assay results did eventually land, they confirmed the same seal-material change the vendor had already told us about — nothing new in it. Interviewer: Let's move to the final decision — what you actually recommended once everything was in. Participant: Once the root cause was locked down, the OEM tech rep raised the idea of a broader design review of the valve seal spec generally, as a longer-term option. But that's a slow, separate track. What I had in front of me was a specific, bounded problem: one vendor lot, identifiable serial ranges. I wrote the corrective action request to replace valves from that lot specifically, not a fleet-wide swap of every valve regardless of lot, and not just deferring to wait on the OEM's broader review. Interviewer: Why bounded to the lot rather than fleet-wide? Participant: Because a fleet-wide replacement would have pulled serviceable, unaffected valves for no reason — that's cost and downtime with no reliability benefit. The evidence pointed specifically at that lot, so that's what I scoped the action to. Interviewer: What happened after you submitted it? Participant: RCB approved the lot-based campaign. Both tails got their valves replaced, and there haven't been further events on either aircraft since. The OEM's broader design review got pushed into a separate long-term study, which is still open as far as I know. Interviewer: Looking back at the whole sequence — is there a point where, with hindsight, you'd handle it differently? Participant: The one thing I go back and forth on is the external lab. I already knew the recommendation wasn't going to move based on what it found — I'd have submitted the same lot-based request either way. Knowing that now, I probably should have just submitted on the original ten-day timeline using the vendor and teardown evidence and let the RCB approve on that, rather than holding the whole submission for a test that was only ever going to restate what I already had. Interviewer: If the assay had come back showing something different from the vendor's account — a different degradation mechanism, say — what would you have done? Participant: I'd have flagged it and opened a separate follow-up investigation into whether the lot-based campaign needed a second look. But that would've come after the fact — I wasn't planning to hold up this submission on that possibility, since I'd already committed to the lot-based recommendation before the assay went out. Interviewer: And if this exact pattern showed up again on a different fleet type — same lot-based signature, same timeline pressure — would you send it out for independent lab work again? Participant: Probably not on the same timeline, honestly. I think I'd ask myself earlier on whether the extra data was likely to change the recommendation I'd already reached or just make the file look better, and weigh that against the deadline more explicitly than I did this time. Interviewer: That's a good place to stop. Thanks for the detail — this is exactly the kind of reconstruction we needed. Participant: No problem. Happy to follow up if anything else comes to mind.

_ranker=rrf · t=0.04 · k=0 → 0 in context · 8192 ctx · emb 0.00s · gen 83.09s · total 87.6s_

_No chunks passed the similarity threshold._

{
  "analysis_metadata": {
    "task": "cognitive_bias_analysis",
    "interview_speakers_detected": [
      "Interviewer",
      "Participant"
    ],
    "retrieved_corpus_support_used": false,
    "analysis_scope_note": "Analysis of a reliability engineer's self-reported reasoning during an APU bleed air valve corrective-action decision, focusing on the decision to obtain an external lab assay after already settling on a lot-based replacement recommendation."
  },
  "identified_bias_summary": [
    {
      "bias_label": "information bias",
      "identified_occurrence_count": 1
    }
  ],
  "identified_occurrences": [
    {
      "occurrence_id": "obs_001",
      "classification_status": "identified",
      "confidence": "high",
      "bias_label": "information bias",
      "alternative_labels": [
        "non-instrumental information seeking",
        "over-testing bias"
      ],
      "taxonomy_status": "established_label",
      "bias_definition": "The tendency to seek or acquire information even when it cannot affect the decision or action at issue, often because the additional information provides reassurance or perceived thoroughness rather than instrumental decision value.",
      "attributed_to_speaker": "Participant",
      "evidence_speaker": "Participant",
      "decision_episode_label": "Decision to send the APU bleed air valve for an external lab assay after already deciding the corrective action and before the RCB deadline.",
      "decision_point_description": "Whether to send the valve sample to an external metallurgical lab for an independent composition assay despite having vendor lot documentation and an in-house teardown that already supported the lot-bounded replacement recommendation.",
      "affected_reasoning_operation": "Information acquisition and testing decision prior to finalizing the Reliability Control Board submission.",
      "bias_specific_mechanism": "The participant sought an additional independent test even though he explicitly stated that the result would not change his recommendation; the test was pursued for reassurance and file completeness rather than for information that could alter the action.",
      "manifestation_in_interview": "The participant sent the valve for an external three-week assay while knowing it would cause the RCB deadline to be missed and while stating that the lot-based replacement recommendation was already settled regardless of what the assay would show.",
      "effect_on_reasoning_or_decision": "The final recommendation was delayed beyond the RCB deadline even though the decision itself was not pending on the external result; the assay ultimately confirmed existing findings and did not change the corrective action.",
      "interview_evidence": [
        {
          "speaker": "Participant",
          "verbatim_quote": "The vendor's lot documentation and our own teardown already lined up on the seal material as the cause, and honestly I'd already decided in my own head that the corrective action was going to be a lot-bounded replacement — that part felt settled. But there was still an option to send the valve out to an external metallurgical lab for an independent composition assay, on top of what I already had.",
          "evidence_explanation": "This shows the participant had already made the substantive recommendation decision before ordering the external assay, framing the assay as additional rather than decision-determining."
        },
        {
          "speaker": "Participant",
          "verbatim_quote": "I sent it out anyway. I'd basically landed on the lot-based replacement regardless of what came back — I wasn't holding the recommendation open pending that result. I think I just wanted a third, fully independent source in the file alongside the vendor's own account of their material, so the package read as more thorough when it went to the board. I knew the lab's turnaround was about three weeks, which meant we'd blow through the RCB deadline before that data came back, and I sent it anyway.",
          "evidence_explanation": "This is the core evidence: he ordered information that he knew would not change the recommendation, would delay the decision, and was sought mainly for perceived thoroughness and reassurance."
        },
        {
          "speaker": "Participant",
          "verbatim_quote": "The recommendation was already written in my head — vendor records and physical teardown agreed, and that's what the corrective action request was going to be built on either way. I think I was after the reassurance of having one more test in the folder more than anything that would've moved the decision itself.",
          "evidence_explanation": "This directly states that the additional test was not intended to move the decision, distinguishing non-instrumental information seeking from ordinary decision-support evidence gathering."
        }
      ],
      "correction_or_counterevidence": "The participant later recognized with hindsight that he likely should have submitted on the original timeline and let the RCB decide using the vendor and teardown evidence. He also stated that if the assay had shown a different degradation mechanism, he would have opened a separate follow-up investigation, suggesting he was not closed to disconfirming evidence, but that such information would not have changed the already-settled current recommendation. The extra test could arguably be justified as risk management or board-facing thoroughness, but the participant's own account indicates it was non-instrumental for the decision itself.",
      "retrieved_corpus_support_available": false,
      "corpus_support_note": "No retrieved scientific-paper corpus passages were available in the provided context. The label 'information bias' is applied from established cognitive-science knowledge; retrieved corpus support was unavailable.",
      "corpus_evidence": []
    }
  ],
  "candidate_biases": [],
  "no_supported_biases_found": false,
  "limitations": [
    "No retrieved corpus passages were provided, so the analysis relies on general cognitive-science knowledge rather than retrieved scientific sources.",
    "The transcript is a single self-report reconstruction and may not fully capture the participant's real-time reasoning or organizational factors."
  ]
}

## Sonnet Prompt 8192

**Q1:** Interviewer: Thanks for making time for this. Just to confirm, this conversation is being recorded for an internal reliability-process review, not a safety investigation into you personally — we're trying to understand how these calls actually get made in practice. That okay with you? Participant: Yeah, that's fine. Happy to walk through it. Interviewer: Great. Can you start by telling me your role and how this particular case landed on your desk? Participant: Sure. I'm a reliability engineer in Maintenance Control. Part of my job is watching for repetitive write-ups across the fleet and deciding when something crosses from 'normal noise' into something that needs a formal corrective action. This one came up because tail 738 logged a third APU bleed air valve write-up inside 45 flight days. Two earlier ones had been closed out as operational check normal, no parts changed, which is pretty typical — a lot of these clear on the bench. Interviewer: Walk me through the incident from the beginning, in your own words. Participant: So the third write-up on 738 is what actually got my attention, because three in that short a window is unusual even though our fleet-wide removal rate for that valve was still sitting inside the OEM's published MTBUR. Nothing screamed 'fleet problem' yet — it looked like it could just be a stubborn individual aircraft. I opened a focused review on that tail rather than calling it a fleet issue outright, and I put a flag on it so I'd get pinged if anything similar showed up elsewhere. Two days later it did — tail 712 logged a lower-severity version of basically the same complaint. That's when line maintenance told me the valve is genuinely hard to bench-test, which raised the possibility we had an intermittent fault that ground checks weren't catching. At that point I pulled the two tails' component histories together and found they shared the same valve batch lot number. That felt like a real thread to pull. Interviewer: What did you do with that lot-number connection? Participant: Company policy is we don't like repeated MEL carryover on the same defect — dispatching with the APU inoperative under MEL is allowed, but doing it leg after leg on the same fault is a flag in itself. Neither aircraft had had an actual in-flight consequence; both faults were caught on the ground. So grounding both outright felt like more than the evidence supported at that point. I put an interim restriction on — one leg of MEL carryover maximum, then it has to be addressed — on both tails, and opened a formal root-cause investigation tied to that lot number. Interviewer: What came back from that investigation? Participant: The vendor quality engineer confirmed that lot had a documented seal-material change about six months earlier. That's a real, traceable cause — not a guess. And our in-house teardown of the valve we'd pulled off 738 showed seal degradation that was consistent with exactly that material change. So by that point I had two independent lines — vendor documentation and physical teardown — pointing at the same thing. Interviewer: Let's slow down on that moment, because I want to understand what happened next. What were you weighing? Participant: Right, so this is the part before I finalized anything for the Reliability Control Board. I had ten days to the RCB deadline. The vendor's lot documentation and our own teardown already lined up on the seal material as the cause, and honestly I'd already decided in my own head that the corrective action was going to be a lot-bounded replacement — that part felt settled. But there was still an option to send the valve out to an external metallurgical lab for an independent composition assay, on top of what I already had. Interviewer: And what did you decide? Participant: I sent it out anyway. I'd basically landed on the lot-based replacement regardless of what came back — I wasn't holding the recommendation open pending that result. I think I just wanted a third, fully independent source in the file alongside the vendor's own account of their material, so the package read as more thorough when it went to the board. I knew the lab's turnaround was about three weeks, which meant we'd blow through the RCB deadline before that data came back, and I sent it anyway. Interviewer: At the time you sent it out, was there anything the assay could tell you that would have changed which corrective action you recommended? Participant: Not really, no. The recommendation was already written in my head — vendor records and physical teardown agreed, and that's what the corrective action request was going to be built on either way. I think I was after the reassurance of having one more test in the folder more than anything that would've moved the decision itself. Interviewer: What happened with the deadline? Participant: We missed presenting a finalized recommendation at that RCB cycle. It slipped to submit-pending-lab-results, even though the recommendation itself wasn't really pending on anything. When the assay results did eventually land, they confirmed the same seal-material change the vendor had already told us about — nothing new in it. Interviewer: Let's move to the final decision — what you actually recommended once everything was in. Participant: Once the root cause was locked down, the OEM tech rep raised the idea of a broader design review of the valve seal spec generally, as a longer-term option. But that's a slow, separate track. What I had in front of me was a specific, bounded problem: one vendor lot, identifiable serial ranges. I wrote the corrective action request to replace valves from that lot specifically, not a fleet-wide swap of every valve regardless of lot, and not just deferring to wait on the OEM's broader review. Interviewer: Why bounded to the lot rather than fleet-wide? Participant: Because a fleet-wide replacement would have pulled serviceable, unaffected valves for no reason — that's cost and downtime with no reliability benefit. The evidence pointed specifically at that lot, so that's what I scoped the action to. Interviewer: What happened after you submitted it? Participant: RCB approved the lot-based campaign. Both tails got their valves replaced, and there haven't been further events on either aircraft since. The OEM's broader design review got pushed into a separate long-term study, which is still open as far as I know. Interviewer: Looking back at the whole sequence — is there a point where, with hindsight, you'd handle it differently? Participant: The one thing I go back and forth on is the external lab. I already knew the recommendation wasn't going to move based on what it found — I'd have submitted the same lot-based request either way. Knowing that now, I probably should have just submitted on the original ten-day timeline using the vendor and teardown evidence and let the RCB approve on that, rather than holding the whole submission for a test that was only ever going to restate what I already had. Interviewer: If the assay had come back showing something different from the vendor's account — a different degradation mechanism, say — what would you have done? Participant: I'd have flagged it and opened a separate follow-up investigation into whether the lot-based campaign needed a second look. But that would've come after the fact — I wasn't planning to hold up this submission on that possibility, since I'd already committed to the lot-based recommendation before the assay went out. Interviewer: And if this exact pattern showed up again on a different fleet type — same lot-based signature, same timeline pressure — would you send it out for independent lab work again? Participant: Probably not on the same timeline, honestly. I think I'd ask myself earlier on whether the extra data was likely to change the recommendation I'd already reached or just make the file look better, and weigh that against the deadline more explicitly than I did this time. Interviewer: That's a good place to stop. Thanks for the detail — this is exactly the kind of reconstruction we needed. Participant: No problem. Happy to follow up if anything else comes to mind.

_ranker=rrf · t=0.04 · k=0 → 0 in context · 8192 ctx · emb 0.00s · gen 87.78s · total 92.2s_

_No chunks passed the similarity threshold._

{
  "analysis_metadata": {
    "task": "cognitive_bias_analysis",
    "interview_speakers_detected": ["Interviewer", "Participant"],
    "retrieved_corpus_support_used": false,
    "analysis_scope_note": "The transcript was analyzed as a standalone interview. No retrieved corpus passages were provided in the input, so corpus support could not be retrieved."
  },
  "identified_bias_summary": [
    {
      "bias_label": "Information bias",
      "identified_occurrence_count": 1
    }
  ],
  "identified_occurrences": [
    {
      "occurrence_id": "obs_001",
      "classification_status": "identified",
      "confidence": "high",
      "bias_label": "Information bias",
      "alternative_labels": ["Information acquisition bias"],
      "taxonomy_status": "established_label",
      "bias_definition": "The tendency to seek or collect additional information that is not needed for the decision at hand and cannot affect the selected course of action.",
      "attributed_to_speaker": "Participant",
      "evidence_speaker": "Participant",
      "decision_episode_label": "Decision to send the APU bleed air valve for an external composition assay despite having already settled the lot-based replacement recommendation",
      "decision_point_description": "After vendor lot documentation and in-house teardown evidence converged on the seal-material cause, the participant considered whether to obtain an independent external composition assay before finalizing the Reliability Control Board recommendation.",
      "affected_reasoning_operation": "Information gathering and evidence acquisition during decision preparation",
      "bias_specific_mechanism": "Seeking an additional diagnostic test that the participant explicitly judged would not change the corrective-action recommendation. The extra information was acquired for reassurance or perceived thoroughness rather than for decision-relevant uncertainty reduction, and it was allowed to delay the recommendation.",
      "manifestation_in_interview": "The participant stated that the lot-based replacement recommendation was already settled before the external lab was used, that the lab could not change that recommendation, and that the lab turnaround would miss the RCB deadline, yet he still sent the valve out for testing.",
      "effect_on_reasoning_or_decision": "The final recommendation missed the original RCB cycle and was delayed as submit-pending-lab-results even though the recommendation was not pending on the lab result. The eventual assay confirmed the existing seal-material finding and did not change the corrective action.",
      "interview_evidence": [
        {
          "speaker": "Participant",
          "verbatim_quote": "I sent it out anyway. I'd basically landed on the lot-based replacement regardless of what came back — I wasn't holding the recommendation open pending that result. I think I just wanted a third, fully independent source in the file alongside the vendor's own account of their material, so the package read as more thorough when it went to the board. I knew the lab's turnaround was about three weeks, which meant we'd blow through the RCB deadline before that data came back, and I sent it anyway.",
          "evidence_explanation": "This quotation shows the participant ordered the lab test even though the corrective-action decision was already made and the test timeline would cause the RCB deadline to be missed."
        },
        {
          "speaker": "Participant",
          "verbatim_quote": "Not really, no. The recommendation was already written in my head — vendor records and physical teardown agreed, and that's what the corrective action request was going to be built on either way. I think I was after the reassurance of having one more test in the folder more than anything that would've moved the decision itself.",
          "evidence_explanation": "This directly states that the assay was non-instrumental: it would not change the recommendation and was sought for reassurance rather than decision-relevant information."
        },
        {
          "speaker": "Participant",
          "verbatim_quote": "We missed presenting a finalized recommendation at that RCB cycle. It slipped to submit-pending-lab-results, even though the recommendation itself wasn't really pending on anything.",
          "evidence_explanation": "This documents the actual consequence: the recommendation was delayed by the unnecessary test, even though the decision did not depend on the test result."
        }
      ],
      "correction_or_counterevidence": "The participant later reflected: \"Knowing that now, I probably should have just submitted on the original ten-day timeline using the vendor and teardown evidence and let the RCB approve on that, rather than holding the whole submission for a test that was only ever going to restate what I already had.\" This is retrospective recognition rather than contemporaneous correction, but it supports the interpretation that the extra test was not decision-relevant.",
      "retrieved_corpus_support_available": false,
      "corpus_support_note": "No retrieved corpus passages were provided with this interview. The label 'Information bias' is used from general cognitive-science knowledge rather than from retrieval; no corpus evidence is available to supply metadata.",
      "corpus_evidence": []
    }
  ],
  "candidate_biases": [],
  "no_supported_biases_found": false,
  "limitations": [
    "No retrieved corpus passages were supplied, so corpus grounding is unavailable for this analysis.",
    "The analysis relies on the participant's retrospective self-report, but the identified mechanism is supported by explicit statements about decision-relevance rather than outcome alone."
  ]
}

